MENU
NEWS
RESEARCH

WORLD CLASS BASIC, TRANSLATIONAL AND CLINICAL RESEARCH

MENU
Prostate Oncobiology - Esther Baena

Esther completed her undergraduate degree in Biology at the University of Seville in Spain. She obtained her PhD in 2006 from the University Autonoma of Madrid, Spain, in Drs Ignacio Moreno de Alborán and Carlos Martínez-A laboratory, advancing the understanding of the role of c-myc essential to the biology of the immune system and blood development. From 2007 to 2011, Esther trained as a postdoctoral fellow in Prof Stuart Orkin’s laboratory at Harvard Medical School (Dana Farber Cancer Institute/Boston Children’s Hospital), funded initially by the Spanish Science Ministry followed by a US Department of Defense Career Development Award. Combining genomics and animal models, she identified a novel cancer gene signature associated with aggressive prostate cancer, which will facilitate the development of more efficient targeted therapies. She joined the CRUK Manchester Institute as a Junior Group Leader in June 2014.

Introduction

Prostate cancer is a very heterogeneous disease both clinically and biologically. New therapies have produced some clinical successes, but a subset of patients progress to incurable castration-resistant PCa (CRPC) and it is not yet possible to predict which patients will respond best to which treatment.

Mouse tumour prostate cells grown in matrigel, where they formed organoids.
Ivana Steiner, Prostate Oncobiology

The initiation of CRPC and metastatic dissemination likely involves the existence of tumour cells, so called cancer-initiating or propagating cells, with the ability to self-renew, survive anti-tumoural treatment effect and interact with the niche to promote daughter cells growth to recapitulate the heterogeneity of the tumour of origin. Despite the number of mutations, recent evidences suggest a key role cell of origin and their reprogrammed niche for the progression of the disease. By combining conditional mouse models, primary cell 3D culture (human and mouse), and genomics, we aim to characterise the molecular pathways that regulate tumour-initiating/propagating cells, which are responsible of tumour recurrence, to develop novel therapeutics that tackle the residual disease.

Selected Publications

Ali A, Hoyle A, Baena E, Clarke NW. (2017)
Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis.
Current Opinion in Urology 27(3):217-224. PubMed abstract

Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC, Orkin SH, Li Z. (2013)
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.
Genes & Development 27(6):683-98. PubMed abstract

Vallespinós M, Fernández D, Rodríguez L, Alvaro-Blanco J, Baena E, Ortiz M, Dukovska D, Martínez D, Rojas A, Campanero MR, Moreno de Alborán I. (2011)
B Lymphocyte commitment program is driven by the proto-oncogene c-Myc.
Journal of Immunology 186(12):6726-36. PubMed abstract

Baena E, Ortiz M, Martínez-A C, de Alborán IM. (2007)
c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+)c-Kit(-) cell generation through p21.
Experimental Hematology 35(9):1333-43. PubMed abstract

Baena E, Gandarillas A, Vallespinós M, Zanet J, Bachs O, Redondo C, Fabregat I, Martinez-A C, de Alborán IM.(2005)
c-Myc regulates cell size and ploidy but is not essential for postnatal proliferation in liver.
Proc Natl Acad Sci U S A 102(20):7286-91. PubMed abstract

de Alborán IM, Baena E, Martinez-A C. (2004)
c-Myc-deficient B lymphocytes are resistant to spontaneous and induced cell death.
Cell Death & Differentiation 11(1):61-8. PubMed abstract

Team

Scientific Officer
Pengbo Wang

Postdoctoral Fellow
Valentina Ubertini

Graduate Student
Ivana Steiner
Alexander Du Feu

ERASMUS Student
Silvia D’Ambrosi

Related Items


Prostate Oncobiology - Projects



Related Links



Download our Annual Report